Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
about
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?
P2860
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
@en
type
label
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
@en
prefLabel
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
@en
P2093
P2860
P356
P1476
Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.
@en
P2093
Fabiana Gentilini
Maria Teresa Petrucci
Marta Chisini
Paola Finsinger
P2860
P304
P356
10.2147/PPA.S38142
P407
P577
2014-07-04T00:00:00Z